All News
Featured Abstracts from Industry at EULAR 2021
Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Read Article
Do look out for Abst #OP0057 today 2/6/21 1645 CEST #EULAR2021. We propose a data-driven algorithm for #rituximab maintenance in #ANCA #vasculitis to avoid excessive retreatment and low IgG @RheumJArn @edvital P. Emery @LeedsMedHealth @LTHTResearch @LeedsHospitals @LeedsBRC https://t.co/XRR0NFnpMu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
🚨So after LoVAS
Now this
Ritux + MMF + Pulse MPS
No oral steroids 🤯
@ARD_BMJ
@EBRheum - Lesser is better ??
https://t.co/CYMNX8wLtd https://t.co/NtwTas3ZdS
EnvisionRheumat ERheumat ( View Tweet)
Positive RCT of Rituximab in Systemic sclerosis https://t.co/WsDZeollu0
Richard Conway RichardPAConway ( View Tweet)
Dr Atienza-Mateo presents on IFX ADA TCZ in Behcets refractory uveitic cystoid macular oedema. All appear effective! @RheumNow #EULAR2021 Abstr#OP0060 https://t.co/Vpju0IvrC5
Richard Conway RichardPAConway ( View Tweet)
Dr Mekinian presents data showing TCZ and TNFi appear equally effective in TAK, complete response 66% vs 70% at 6 months @RheumNow #EULAR2021 Abstr#OP0068
Richard Conway RichardPAConway ( View Tweet)
Dr Sanchez-Bilbao presents surprising data that tocilizumab may improve even permanent vision loss in GCA @RheumNow #EULAR2021 Abstr#OP0065 https://t.co/oFGNZ04oKr
Richard Conway RichardPAConway ( View Tweet)
Dr Arnold @Yuz6Yusof present on personalised rituximab retreatment in AAV. Interesting that naive B-cell repopulation at 6 months predicts better sustained response compared to absence @RheumNow #EULAR2021 Abstr#OP0057 https://t.co/cypyQVMeYz
Richard Conway RichardPAConway ( View Tweet)
@jeffsparks knocking it out of the park presenting our findings on b/tsDMARD associations with COVID-19 outcomes @eular_org @EULAR_Press check out our full paper just published in @ARD_BMJ https://t.co/jcA1LN45R3
Zach Wallace zach_wallace_md ( View Tweet)
Secukinumab effective in AS patients, irrespective of gender
AQUILA 52 week study
⭐️improvement in BASDAI, PGA, severity of depressive mood in both men and women
⭐️women had overall higher disease burden in global functioning and depressive mood
POS0899
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Atienza-Mateo presents abstract #POS0595 on abatacept in RA-ILD. Abatacept surprisingly appeared to be equally good in stabilising FVC and DLCO in both UIP and NSIP patterns in RA-ILD. @RheumNow #EULAR2021 Abstr#POS0595 https://t.co/kHUxWXnaBG
Richard Conway RichardPAConway ( View Tweet)
C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA
⭐️82% ⬇️ in uveitis flare event
⭐️reduction in axSpA disease activity
⭐️no new safety signals
POS0897 #EULAR2021 @RheumNow https://t.co/182iHfkSTY
Robert B Chao, MD doctorRBC ( View Tweet)
Yes more lab abnormalities in #Upadactinib vs #Adalimumab in RA RCTs including cytopenias, transaminitis but not creatinine @RheumNow @eular_org #EULAR2021 but no diff in treatmt emergent Adverse events abst OP0128 Yes do labs when on #Upadacitinib https://t.co/5ypKGxuE3U https://t.co/XRjr0gDnIT
Janet Pope Janetbirdope ( View Tweet)
The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden in PsA patients. #EULAR2021 @RheumNow Poster #POS0194 https://t.co/FaIZ7LcoNj
Dr. Rachel Tate uptoTate ( View Tweet)
The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden. What drug class do you choose as first line therapy for your PsA patients with prominent enthesitis? #EULAR2021 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Lifetime risk of HZ is 30%! ⬆️ in pts with immune diseases or immunesuppression. All #JAKI ⬆️ risk maybe doubling but NNH & NNT give context. UPA Rx in active RA -20 more pts in remission vs 1 excess HZ if comparing UPA to ADA in RA @RheumNow #EULAR2021 AbbVie symposium https://t.co/14i0IsIpzs
Janet Pope Janetbirdope ( View Tweet)
Hands-Down Rheumatology - Sarcoidosis usually presents as a monarthritis or oligoarthritis. Late sarcoid arthritis affects knees, ankles, fingers (dactylitis). Bony lesions show honeycomb trabecular pattern). https://t.co/lmXBbJz6ts
Links:
Dr. John Cush RheumNow ( View Tweet)
Top May Tweet: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w
Links:
Dr. John Cush RheumNow ( View Tweet)
News: Triple DMARD Therapy Bested by Biologics in Swedish Registry
The Swedish Register compared outcomes of 1502 RA patients initiating either biologics plus MTX or triple therapy and showed similar rates of sustained remission.
https://t.co/7JJxGF1tHz https://t.co/ht6kAsJkb9
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Heart, Lung & Liver (5.28.2021)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article